Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 633

Results For "CE"

9357 News Found

Cipla to further invest Rs. 42 crore in GoApptiv
Digitisation | December 17, 2023

Cipla to further invest Rs. 42 crore in GoApptiv

Expands patient reach to remotest towns by furthering investment in GoApptiv


Pfizer expects 2024 revenue between US$ 58.5 to US$ 61.5 billion
News | December 14, 2023

Pfizer expects 2024 revenue between US$ 58.5 to US$ 61.5 billion

Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid


Pfizer presents marstacimab Phase 3 Data at ASH 2023
News | December 10, 2023

Pfizer presents marstacimab Phase 3 Data at ASH 2023

Demonstrate significant bleed reduction in hemophilia A and B


Aptar Pharms opens new production facility at Taloja, Mumbai
News | December 10, 2023

Aptar Pharms opens new production facility at Taloja, Mumbai

New facility is part of Aptar Pharma’s global expansion program


Max Healthcare acquires 550 bedded Sahara Hospital, Lucknow
Healthcare | December 09, 2023

Max Healthcare acquires 550 bedded Sahara Hospital, Lucknow

This acquisition marks Max Healthcare's entry into Lucknow


Fire accident at Parmax Pharma’s plant
News | December 09, 2023

Fire accident at Parmax Pharma’s plant

There has been no loss or injury to human life


European Commission approves Pfizer’s Elrexfio for multiple myeloma
Drug Approval | December 09, 2023

European Commission approves Pfizer’s Elrexfio for multiple myeloma

Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial


Zepbound is now available in US for adults living with obesity
News | December 09, 2023

Zepbound is now available in US for adults living with obesity

Express Scripts to add Zepbound to National Preferred Formulary


Sarclisa Phase 3 trial met primary endpoint of progression free survival with newly diagnosed multiple myeloma not eligible for transplant
News | December 08, 2023

Sarclisa Phase 3 trial met primary endpoint of progression free survival with newly diagnosed multiple myeloma not eligible for transplant

Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone


AbelZeta Pharma, AstraZeneca to co-develop a novel GPC3 armored CAR-T therapy in China
News | December 08, 2023

AbelZeta Pharma, AstraZeneca to co-develop a novel GPC3 armored CAR-T therapy in China

C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II